Tevogen bio's r&d leadership discusses the promise of its genetically unmodified, off-the-shelf t cell technology for the treatment of infectious diseases, cancers, and neurological disorders with nasdaq's kristina ayanian

Warren, n.j., july 10, 2024 (globe newswire) -- dr. neal flomenberg and dr. lori grosso of tevogen bio holding inc. (“tevogen” or “tevogen bio”) (nasdaq: tvgn), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified t cell therapeutics in oncology, neurology, and virology, discussed the promise of t cell therapy and tevogen's mission to make it mainstream on nasdaq's broadcast, live from marketsite with kristina ayanian.
NDAQ Ratings Summary
NDAQ Quant Ranking